Hypertrophy of intima media of the carotid artery due to L-dopa therapy in Parkinson's disease

Advances in Therapy

Volumn 25, Issue 3, 2008, Pages 201-207

  Öncel, Çaǧatay ^a,c   Ince, Birsen ^b   Apaydin, Hülya ^b   Özekmekçi, Sibel ^b   Uludüz, Derya ^b  

^a PAMUKKALE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c Hastane Cad   (Turkey)

Author keywords

Carotid; Intima media thickness; L dopa

Indexed keywords

CABERGOLINE; LEVODOPA; PERGOLIDE; PRAMIPEXOLE;

ARTERIAL WALL THICKNESS; ARTICLE; B SCAN; CAROTID ARTERY; CLINICAL ARTICLE; COLOR ULTRASOUND FLOWMETRY; COMMON CAROTID ARTERY; CONTROLLED STUDY; EXTERNAL CAROTID ARTERY; FEMALE; HUMAN; INTERNAL CAROTID ARTERY; MALE; PARKINSON DISEASE; SCORING SYSTEM; SIDE EFFECT; TREATMENT DURATION;

EID: 59249099125     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12325-008-0035-9     Document Type: Article

References (13)

1. Burke GL, Evans GW, Riley WA, et al. Arterial wall thickness is associated with prevalent cardiovascular disease in middleaged adults: the Atherosclerosis Risk In Communities (ARIC) study. Stroke. 1995;26:386-391.
2. Grobbee DE, Bots ML. Carotid intimamedia thickness as an indicator of generalized atherosclerosis. J Intern Med. 1994;236:567-573.
3. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction. Circulation. 1997;96:1432-1437.
4. Nakaso K, Yasui K, Kowa H, et al. Hypertrophy of IMC of carotid artery in Parkinson's disease is associated with L-DOPA, homocysteine, and MTHFR genotype. J Neurol Sci. 2003;207:19-23.
5. Shannon KM. Rating scales. In: Ebadi M, Pfeiffer RF, eds. Parkinson's Disease. Florida: CRC Press; 2005:663-677.
6. Zureik M, Touboul PJ, Bonithon Kopp C, et al. Cross-sectional and 4-year longitudinal associations between brachial pulse pressure and common carotid intimamedia thickness in a general population. Stroke. 1999;30:550-555.
7. Hassin-Baer S, Cohen O, Vakil E, et al. Plasma homocysteine levels and Parkinson disease: Disease progression, carotid intimamedia thickness and neuropsychiatric complications. Clin Neuropharmacol. 2006;29:305-311.
8. Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. Lancet. 1999;354:407-413.
9. Ozer F, Meral H, Hanoglu L, et al. Plasma homocysteine levels in patients treated with levodopa: Motor and cognitive associations. Neurol Res. 2006;28:853-858.
10. Zoccolella S, Lamberti P, Armenise E, et al. Plasma homocysteine levels in Parkinson's disease: Role of antiparkinsonian medications. Parkinsonism Relat Disord. 2005;11:131-133.
11. Martignoni E, Tassorelli C, Nappi G, Zangaglia R, Pacchetti C, Blandini F. Homocysteine and Parkinson's disease: A dangerous liaison? J Neurol Sci. 2007;257:31-37.
12. Religa D, Czyzewski K, Styczynska M, et al. Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson's disease. Neurosci Lett. 2006;404:56-60.
13. Widner B, Leblhuber F, Frick B, Laich A, Artner-Dworzak E, Fuchs D. Moderate hyperhomocysteinaemia and immune activation in Parkinson's disease. J Neural Transm. 2002;109:1445-1452.